Table 2 Clinical characteristics and treatments of the RA-CAD and pure RA groups
|  | RA-CAD (n = 54) | RA (n = 43) | p value |
|---|---|---|---|
Morning stiffness > 1 h | 32 (59.3%) | 21 (48.8%) | NS |
Dry mouth (%) | 25 (46.3%) | 19 (44.2%) | NS |
Dry eye (%) | 12 (22.2%) | 11 (25.6%) | NS |
Back pain (%) | 8 (14.8%) | 5 (11.6%) | NS |
Treated/untreated | 33/21 | 28/15 | NS |
GCs (prednisone 2.5–10mgday) (%) | 19/54 (35.2%) | 18/43 (41.9%) | NS |
DMARDs (MTX/LEF/HCQ) (%) | 23/54 (42.6%) | 18/43 (41.9%) | NS |
NSAIDs (%) | 16/54 (29.6%) | 15/43 (34.9%) | NS |
Biologics (rhTNFR-Fc) (%) | 5/54 (9.3%) | 1/43 (2.3%) | NS |
Statins (%) | 32/54 (59.3%) | – | – |
Anti-platelet drug (%) | 25/54 (46.3%) | – | – |
Beta-blockers (%) | 9/54 (16.7%) | – | – |
ACEI/ARBs (%) | 4/54 (7.4%) | – | – |
Coronary-expansion drugs (%) | 10/54 (18.5%) | – | – |